Sebia enters into agreement with Sanofi to develop multiple myeloma diagnostic test
The tests will specifically adjust for isatuximab-induced interference in complete response assessment of multiple myeloma patients
7 Jan 2020
Industry news
Sebia has announced that it is entering into an agreement with Sanofi to develop an in vitro diagnostic (IVD) test that mitigates the potential interference caused by isatuximab in Immunofixation Electrophoresis (IFE) tests. Sebia will develop the test and act as worldwide supplier. The financial details have not been disclosed.
Isatuximab is an investigational monoclonal antibody (mAb) that targets a specific epitope of CD38 capable of triggering multiple mechanisms of action that are believed to promote programmed tumor cell death and immunomodulatory activity.
New multiple myeloma therapies that use biologics, specifically mAbs, are known to interfere with the patient’s monoclonal protein in IFE tests. This can mislead healthcare professionals in interpreting the patient’s response to therapy; Immunofixation is one of the tests referenced in the International Myeloma Working Group (IMWG) guidelines to diagnose complete response in a patient with multiple myeloma.
This agreement covers the development of the Hydrashift 2/4 isatuximab IVD kit to be used in conjunction with Sebia’s proprietary IFE assay, Hydragel. This IVD test is specifically for patients treated with isatuximab and is only used on Sebia’s FDA cleared and CE marked Hydrasys 2 platform.
“We are excited about partnering with Sanofi and further developing our Immunofixation range of products. The future Hydrashift 2/4 isatuximab test is in line with our strategy of developing innovative and advanced products for patient care,” said Jean-Marc Chermette, CEO at Sebia. “This development confirms Sebia’s commitment and strategic objective to remain the market leader in providing the most advanced diagnostic tools supporting multiple myeloma disease management.”
Want more of the latest science news straight to your inbox? Become a SelectScience member today for free>>
Related products
Request Quote for All Products
CAPILLARYS™ 2
Sebia (UK) LimitedFully Automated Capillary Electrophoresis System Sebia's innovative capillary electrophoresis system is designed to optimize and completely automate electrophoresis testing. The CAPILLARYS 2 utilizes liquid flow electrophoresis for applications in the clinical diagnostic setting. Continuous sample feed and the use of eight very narrow capillary tubes functioning concurrently provide a high throughput of up to 80 Protein samples per hour. The direct detection of proteins at a precise wavelength, which is assay dependent, improves accuracy and linearity and eliminates the need for staining. A patented, protected capillary horseshoe design provides for: Tight temperature control during sample migration, generating consistent reproducible results from analysis–to–analysis and from capillary–to–capillary. Extended capillary life of greater than 3,000 samples per capillary — or greater than 24,000 samples per test system. Sebia's capillary electrophoresis instrument provides complete walk-away automation from bar-coded primary sample tube to final result - positive sample ID.
Minicap Flex Piercing
Sebia (UK) LimitedThe Sebia capillary electrophoresis automated solution for small to medium size laboratories